Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Simbols: 002693.SZ
SHZ
5.18
CNYTirgus cena šodien
2322.2660
P/E koeficients
-133.5303
PEG koeficients
2.14B
MRK Cap
- 0.00%
DIV ienesīgums
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693-SZ) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 512.21 | 146 | 77 | 100 | ||||||||||||||
balance-sheet.row.short-term-investments | 447.02 | 133.8 | 55.4 | 94.3 | ||||||||||||||
balance-sheet.row.net-receivables | 144.81 | 41 | 33.1 | 44.6 | ||||||||||||||
balance-sheet.row.inventory | 291.75 | 65.4 | 55.2 | 52.8 | ||||||||||||||
balance-sheet.row.other-current-assets | 0.05 | 0 | 0.1 | 0 | ||||||||||||||
balance-sheet.row.total-current-assets | 948.81 | 252.4 | 165.4 | 197.5 | ||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1849.45 | 471.8 | 504.7 | 541 | ||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.intangible-assets | 668.54 | 164.9 | 156.9 | 134.4 | ||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 668.54 | 164.9 | 156.9 | 134.4 | ||||||||||||||
balance-sheet.row.long-term-investments | 42.28 | 8.8 | 17.3 | 25.9 | ||||||||||||||
balance-sheet.row.tax-assets | 3.67 | 1 | 1 | 0.7 | ||||||||||||||
balance-sheet.row.other-non-current-assets | 53.66 | 12.2 | 9.1 | 8.3 | ||||||||||||||
balance-sheet.row.total-non-current-assets | 2617.6 | 658.6 | 689.1 | 710.2 | ||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.total-assets | 3566.42 | 911 | 854.6 | 907.7 | ||||||||||||||
balance-sheet.row.account-payables | 59.55 | 15.5 | 17.2 | 15.4 | ||||||||||||||
balance-sheet.row.short-term-debt | 774.46 | 205.3 | 0.3 | 55.7 | ||||||||||||||
balance-sheet.row.tax-payables | 23.85 | 12.8 | 7.2 | 6.3 | ||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 167 | 167 | ||||||||||||||
Deferred Revenue Non Current | 30.41 | 7.6 | 8.9 | 10.3 | ||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 12.16 | - | - | - | ||||||||||||||
balance-sheet.row.other-current-liab | 144.47 | 73.6 | 1.8 | 1.5 | ||||||||||||||
balance-sheet.row.total-non-current-liabilities | 42.56 | 10.7 | 179.4 | 180 | ||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.total-liab | 1235.79 | 330.1 | 287.8 | 309.4 | ||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||
balance-sheet.row.common-stock | 1662.29 | 414.7 | 412 | 405 | ||||||||||||||
balance-sheet.row.retained-earnings | -1173.2 | -296.2 | -305.2 | -284.6 | ||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 1000.92 | 87.2 | 82.2 | 86 | ||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 600.88 | 307.9 | 292.9 | 286.5 | ||||||||||||||
balance-sheet.row.total-stockholders-equity | 2090.9 | 513.5 | 481.8 | 492.9 | ||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 3566.42 | 911 | 854.6 | 907.7 | ||||||||||||||
balance-sheet.row.minority-interest | 239.74 | 67.4 | 84.9 | 105.4 | ||||||||||||||
balance-sheet.row.total-equity | 2330.63 | 580.9 | 566.8 | 598.3 | ||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 3566.42 | - | - | - | ||||||||||||||
Total Investments | 447.02 | 133.8 | 55.4 | 94.3 | ||||||||||||||
balance-sheet.row.total-debt | 774.46 | 205.3 | 167.3 | 222.7 | ||||||||||||||
balance-sheet.row.net-debt | 709.27 | 193.1 | 145.6 | 216.9 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0.93 | -8.5 | -40.8 | -79.9 | ||||||||||||||
cash-flows.row.depreciation-and-amortization | 16.06 | 57.5 | 54.3 | 57.1 | ||||||||||||||
cash-flows.row.deferred-income-tax | 5.29 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.stock-based-compensation | 8.3 | 6.9 | 7.2 | -1.2 | ||||||||||||||
cash-flows.row.change-in-working-capital | -23.72 | -4.5 | 14.9 | -12.2 | ||||||||||||||
cash-flows.row.account-receivables | -13.83 | -13.8 | 5.4 | 39.8 | ||||||||||||||
cash-flows.row.inventory | -9.89 | -9.9 | -4.8 | -4.3 | ||||||||||||||
cash-flows.row.account-payables | 0 | 19.6 | 13.8 | -48.9 | ||||||||||||||
cash-flows.row.other-working-capital | 0 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.other-non-cash-items | -5.52 | -25.8 | -12.5 | 24.5 | ||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -0.08 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -39.11 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.acquisitions-net | 30.81 | 27 | 21.7 | 53.6 | ||||||||||||||
cash-flows.row.purchases-of-investments | -418.83 | -471 | -256.2 | -637.2 | ||||||||||||||
cash-flows.row.sales-maturities-of-investments | 456.59 | 391.9 | 299.2 | 615.3 | ||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | -51.6 | ||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 29.47 | -85.1 | 33 | -71.5 | ||||||||||||||
cash-flows.row.debt-repayment | -60.74 | -12 | -55.3 | -1.8 | ||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.dividends-paid | -8.7 | -11.1 | -9.1 | -9.8 | ||||||||||||||
cash-flows.row.other-financing-activites | 38.34 | 68.1 | 23.8 | 57 | ||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -31.1 | 44.9 | -40.6 | 45.4 | ||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.02 | 0.1 | -0.1 | -0.3 | ||||||||||||||
cash-flows.row.net-change-in-cash | 1.46 | -14.8 | 15.8 | -36.9 | ||||||||||||||
cash-flows.row.cash-at-end-of-period | 59.79 | 6.8 | 21.6 | 5.8 | ||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 58.33 | 21.6 | 5.8 | 42.7 | ||||||||||||||
cash-flows.row.operating-cash-flow | -0.08 | 25.2 | 23.6 | -10.5 | ||||||||||||||
cash-flows.row.capital-expenditure | -39.11 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.free-cash-flow | -39.19 | -7.8 | -8.1 | -62.1 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 259.14 | 274.8 | 320.3 | 269.4 | ||||||||||||||
income-statement-row.row.cost-of-revenue | 77.43 | 88.3 | 81.4 | 60.2 | ||||||||||||||
income-statement-row.row.gross-profit | 181.71 | 186.5 | 238.9 | 209.3 | ||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||
income-statement-row.row.research-development | 14.15 | - | - | - | ||||||||||||||
income-statement-row.row.selling-general-administrative | 14.02 | - | - | - | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 115.8 | - | - | - | ||||||||||||||
income-statement-row.row.other-expenses | 71.77 | 63.2 | 69 | 69.7 | ||||||||||||||
income-statement-row.row.operating-expenses | 210.16 | 215.8 | 282.7 | 264.6 | ||||||||||||||
income-statement-row.row.cost-and-expenses | 287.59 | 304.1 | 364.1 | 324.8 | ||||||||||||||
income-statement-row.row.interest-income | 0.1 | 0.1 | 0.1 | 0.1 | ||||||||||||||
income-statement-row.row.interest-expense | 10.15 | 11.2 | 9 | 10 | ||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 115.8 | - | - | - | ||||||||||||||
income-statement-row.row.total-other-income-expensenet | -0.05 | 15.6 | 2 | -25.6 | ||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||
income-statement-row.row.other-operating-expenses | 71.77 | 63.2 | 69 | 69.7 | ||||||||||||||
income-statement-row.row.total-operating-expenses | -0.05 | 15.6 | 2 | -25.6 | ||||||||||||||
income-statement-row.row.interest-expense | 10.15 | 11.2 | 9 | 10 | ||||||||||||||
income-statement-row.row.depreciation-and-amortization | -9.92 | 57.5 | 54.3 | 57.1 | ||||||||||||||
income-statement-row.row.ebitda-caps | -22.8 | - | - | - | ||||||||||||||
income-statement-row.row.operating-income | -12.88 | -24.5 | -42.3 | -53.2 | ||||||||||||||
income-statement-row.row.income-before-tax | -12.93 | -8.9 | -40.4 | -78.8 | ||||||||||||||
income-statement-row.row.income-tax-expense | -8.64 | -0.4 | 0.4 | 1.2 | ||||||||||||||
income-statement-row.row.net-income | 0.93 | -8.5 | -40.8 | -79.9 |
Biežāk uzdotie jautājumi
Kas ir Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) kopējie aktīvi?
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) kopējie aktīvi ir 911018789.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir 100763670.000.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.701.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -0.095.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.004.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir -0.050.
Kāda ir Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -8496001.960.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 205303152.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 215787255.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 3712099.000.